Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

2009 ◽  
Vol 157 (5) ◽  
pp. 845-852 ◽  
Author(s):  
Mark J. Sculpher ◽  
Greta Lozano-Ortega ◽  
Jennifer Sambrook ◽  
Stephen Palmer ◽  
Orges Ormanidhi ◽  
...  
2010 ◽  
Vol 13 (7) ◽  
pp. A353
Author(s):  
PA Vorobyev ◽  
O Borisenko ◽  
M Lesnicheva ◽  
S Shiganov ◽  
A Lomakin

1970 ◽  
Vol 110 (4) ◽  
pp. 77-80
Author(s):  
M. R. Babarskiene ◽  
J. Vencloviene ◽  
D. Luksiene ◽  
I. Milvidaite

Ischemic heart disease is the leading cause of death in Europe among males over 45 years of age and females older than 65. The aim of the study: to evaluate the informative value of the models in ACS patients using GRACE (GR) risk score, to identify additional informative indicators for short-term and long-term prognosis following ACS, and to evaluate the prognostic reliability of the integrated model. The study included 1491 patients who in 2005 were treated for ACS in the Department of Cardiology, the Hospital of Kaunas University of Medicine. We devised an adjusted prognostic index for making short and long-term prognosis in patients with acute coronary syndromes (STEMI and NSETMI). Following adjustment of the GR scores, the prognostic value improved for STEMI patients. Ill. 2, bibl. 12, tabl. 3 (in English; abstracts in English and Lithuanian).http://dx.doi.org/10.5755/j01.eee.110.4.292


2018 ◽  
Vol 2 (6) ◽  
pp. 377-383
Author(s):  
Harry P. Selker ◽  
Manlik Kwong ◽  
Robin Ruthazer ◽  
Sheeona Gorman ◽  
Giuliana Green ◽  
...  

AbstractBackground:To identify potential participants for clinical trials, electronic health records (EHRs) are searched at potential sites. As an alternative, we investigated using medical devices used for real-time diagnostic decisions for trial enrollment.Methods:To project cohorts for a trial in acute coronary syndromes (ACS), we used electrocardiograph-based algorithms that identify ACS or ST elevation myocardial infarction (STEMI) that prompt clinicians to offer patients trial enrollment. We searched six hospitals’ electrocardiograph systems for electrocardiograms (ECGs) meeting the planned trial’s enrollment criterion: ECGs with STEMI or > 75% probability of ACS by the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI). We revised the ACI-TIPI regression to require only data directly from the electrocardiograph, the e-ACI-TIPI using the same data used for the original ACI-TIPI (development set n = 3,453; test set n = 2,315). We also tested both on data from emergency department electrocardiographs from across the US (n = 8,556). We then used ACI-TIPI and e-ACI-TIPI to identify potential cohorts for the ACS trial and compared performance to cohorts from EHR data at the hospitals.Results:Receiver-operating characteristic (ROC) curve areas on the test set were excellent, 0.89 for ACI-TIPI and 0.84 for the e-ACI-TIPI, as was calibration. On the national electrocardiographic database, ROC areas were 0.78 and 0.69, respectively, and with very good calibration. When tested for detection of patients with > 75% ACS probability, both electrocardiograph-based methods identified eligible patients well, and better than did EHRs.Conclusion:Using data from medical devices such as electrocardiographs may provide accurate projections of available cohorts for clinical trials.


Sign in / Sign up

Export Citation Format

Share Document